Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PALI
- Price
- 0.70
- Stock movement up
- +0.02 (2.50%)
- Company name
- Palisade Bio Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 993.43K
- Ent value
- -4.32M
- Price/Sales
- -
- Price/Book
- 0.15
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -64.62%
- 1 year return
- -82.87%
- 3 year return
- -90.24%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PALI does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.15 |
| EV to Sales | 17.27 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.43M |
| EPS (TTM) | -9.37 |
| FCF per share (TTM) | -8.37 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | -250.00K |
| Gross profit (TTM) | -306.00K |
| Operating income (TTM) | -14.77M |
| Net income (TTM) | -14.06M |
| EPS (TTM) | -9.37 |
| EPS (1y forward) | -3.81 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 122.40% |
| Operating margin (TTM) | 5907.20% |
| Profit margin (TTM) | 5626.00% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 8.04M |
| Net receivables | 96.00K |
| Total current assets | 8.87M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 9.34M |
| Accounts payable | 366.00K |
| Short/Current long term debt | 357.00K |
| Total current liabilities | 2.68M |
| Total liabilities | 2.73M |
| Shareholder's equity | 6.61M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -12.56M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -12.56M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -212.85% |
| Return on Assets | -150.65% |
| Return on Invested Capital | -201.94% |
| Cash Return on Invested Capital | -180.30% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.68 |
| Daily high | 0.70 |
| Daily low | 0.67 |
| Daily Volume | 28K |
| All-time high | 44820.00 |
| 1y analyst estimate | 30.33 |
| Beta | 1.33 |
| EPS (TTM) | -9.37 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| PALI | S&P500 | |
| Current price drop from All-time high | -100.00% | -12.89% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 3 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -98.75% | -11.07% |
| Avg time to new high | 997 days | 12 days |
| Max time to new high | 996 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
993.43K
Marketcap category
Small-cap
Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
Employees
9
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page